Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 5
Submit an article Journal homepage
2,834
Views
16
CrossRef citations to date
0
Altmetric
Editorial

Open innovation: the new face of pharmaceutical research and development

Kenneth A Getz Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA
&
Kenneth I Kaitin Tufts Center for the Study of Drug Development, Tufts University School of Medicine Boston, MA, USA. [email protected]
Pages 481-483 | Published online: 10 Jan 2014

References

  • Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10(6), 428–438 (2011).
  • DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87(3), 272–277 (2010).
  • Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin. Pharmacol. Ther. 89(2), 183–188 (2011).
  • Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8(12), 959–968 (2009).
  • DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ. 28(4–5), 469–479 (2007).
  • World Preview 2016 Report. Evaluate Pharma, DE, USA (2010).
  • Getz KA, Zuckerman R, DiMasi JA, Kaitin KI. Drug development portfolio and spending practices after mergers and acquisitions. Drug Info. J. 43(4), 493–500 (2009).
  • Getz KA, Campo RA, Kaitin KI. Variability in protocol design complexity by phase and therapeutic area. Drug Info. J. 45(4), 413–420 (2011).
  • Getz K, Zuckerman R, Cropp A, Hindle A, Krauss R, Kaitin K. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Info. J. 45(4), 265–275 (2011).
  • Kaitin K (Ed.). Rising demand is expanding scope and workload of regulatory affairs function. Tufts CSDD Impact Reports 12(2), (2010).
  • Getz KA, Vogel JR. Successful outsourcing: tracking global CRO usage. Appl. Clin. Trials Online 17, 39–44 (2009).
  • Hunter J. Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 2(9), 87–88 (2010).
  • Kaitin KI. 21st century bioinnovation: academic–industry partnerships are increasingly important in biopharmaceutical innovation. Pharma. Technol. 35(6), 32 (2011).
  • Getz K. FIPNet: pharma’s new, sexy, but not yet ready for print-time model. Appl. Clin. Trials (Suppl.), 10–16 (2009).
  • Kaitin KI. Creating innovation nodes to meet unmet medical needs: pharma companies must balance demand for new drugs while facing reduced R&D spending. Pharma. Technol. 35(12), 27 (2011).
  • Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87(3), 356–361 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.